CLINICS IN S GERIATRIC MEDICINE Clin Geriatr Med 19 (2003) 857—873 Cumulative Index 2003 Volume 19 February RESPIRATORY DISEASE IN THE ELDERLY, pages 1-244 May OSTEOPOROSIS, pages 245-462 August GERIATRIC SEXUALITY, pages 463-662 November GERIATRIC MENTAL HEALTH, pages 663-873 Note: Page numbers of article titles are in boldface type. A inpatient versus residential treatment of, Absorptiometry, prediction of hip fracture 153- 154 using, 286, 287 prevalence of, 744-746 i self-help group meetings in, 756—757 Advanced care planning, in chronic obstructive treatment of, 751—753 pulmonary disease, 226 : in congestive heart failure, 226 Alcohol use disorders test, 752 patient preferences and, 227 Alcoholic patients, alcohol-related problems in, Affective disorders, antipsychotics for, 707 diagnosis of, 750 psychotic symptoms in, 707 effects of alcohol ve ie ¥ bade patterns of problem drinking in, Age, as factor in risk for osteoporosis, 747-748 246-247 Alcoholics Anonymous, 756—757 Aging, bone remodeling and, 263-267 a ; J libido with, 467 Alendronate, clinical trials of, 399-400 current use of, 401 AIDS and HIV. See HIV and AIDS. parathyroid hormone and, in osteoporosis, 428 AIDS-related dementia, and Alzheimer’s tolerability and side effects of, 401 disease, features of, 651 : ' eles Alprazolam, 710 Alcohol, intake of. See also Drinking. benefits and risks of, 331 Alzheimer’s disease, 769-770 by older adults, 684-687 accelerated brain aging and, 623-624 moderate, as protective, 685 and AIDS-related dementia, features sexual function and, 560 of, 651 4 and other dementias, 763—776 Alcohol abuse/dependence, in older adults, peat aL Ng ; : conditions mimicking, 766 detection of, 685-687 ae saat eae rae Mae depression of, diagnostic criteria for, 808 incidence of, 685—687 spe pg S risk of, hormone replacement therapy Alcohol dependence, background of, 744 and, 623, 624 collateral medical and psychiatric treatment of deficits in, 766—767 treatment in, 754—755 ‘ ’ - ih ia diagnosis of, and treatment of, scar Sanaehy hine sr Medicine 743-761 patient criteria, 753, 75 barriers to, 745-746 Anal eroticism, 634—635 individual and group therapy in, 755-756 Androgens, in erectile dysfunction, 534 0749-0690/03/$ — see front matter © 2003 Elsevier Inc. All rights reserved. doi: 10.1016/S0749-0690(03 )00056-9 858 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 Andropause, 507-528 laboratory investigations of, 730 assays for, 520 management of, 730—733 behavioral effects of, 607 pharmacologic treatment in, 730-733 pathophysiology of, 509-510 psychologic treatments in, 733-735 screenings for, for primary care settings, Andropause questionnaires, 518-520 729-730 Anesthesia, as risk factor in pulmonary selective serotonin reuptake inhibitors surgery, 45—46 in, 731 serotonin/norepinephrine reuptake Angiography, pulmonary, to diagnose inhibitors in, 732 pulmonary embolism, 164 symptoms of, 722 Ankle, fractures of, antiglideplate and, Anxiety disorder(s), 677-681 449, 450 antidepressants in, 699 Antibiotics, in dementia, 849 characteristics of, 723-726 comorbidity of, 681 Anticholinergic toxicity, 713 depression and, 672 Anticonvulsants, 708—710 frequency of, 722 electroconvulsive therapy and, 833 generalized, 724 sexual function and, 560 in older adults, 721-741 prevalence of, 677—678 Antidepressants, 698 —7 03 adverse effects of, 700 Anxiolytic drugs, sexual function and, 556 in bipolar disorder, 794 Apathy, diagnostic criteria for, 807 in dementia, 814 in special elderly populations, 699-700 Apnea index, 183 plus psychotherapy, 698 Apomorphine, in erectile dysfunction, 534 sexual function and, 555 tricyclic, 700-701 Apomorphine SL, in erectile dysfunction, 479 Anti-estrogens, selective, 373-381 Aripiprazole, 706—707 in dementia, 816 Antiglideplate, fractures of ankle and, 449, 450 Arterial blood gas values, in pulmonary Antihypertensive drugs, sexual function and, embolism, 160 556-557 Arthritis, sexual dysfunction and, 567-568 Anti-inflammatory agents, in asthma, 66—68 Asthma, abnormal neurogenic influences in, 59 Antipsychotics, 703 —707 airway obstruction in, 60 adverse drug reactions with, 704 airway responsiveness in, 59-60 adverse effects of, 703 atopic, 60-61 and hyperlipidemia, 705 bronchial hyperresponsiveness in, 59 and weight gain, 704—705 clinical characterisitcs of, 63-64 for affective disorders, 707 clinical outcome and prognosis in, 71 hyperprolactinemia due to, 703-704 definition of, 57 in bipolar disorder, 793 epidemiology of, 62—63 movement disorders induced by, histopathologic findings in, 58-59 703 —704 in elderly, 57-75 new-onset diabetes and, 705 fixed airflow obstruction in, 64 Anxiety, and medical illness, 726—727 inhalation therapy in, 70—71 as adaptive emotional reaction, 721 —722 non-atopic, 61 —62 assessment of, with rating scales, pathophysiology of, 58—62 728-729 postoperative pulmonary complications atypical neuroleptics in, 733 in, 42 azapirones, 733 treatment of, 65—66 benzodiazepines in, 732 by severity of disease, 67 clinical evaluation of, 728—730 medication for, 66—70 collaborative models of care in, 735—736 Autonepiophilia, 634 comorbid, and depression, 727-728 end-of-life care in, 844—845 Autonomic system, during normal aging of in dementia, 680 respiratory system, |1—12 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 B metabolism of, pathophysiology of Back, exercise to strengthen, 341 estrogen deficiency on, 364 extensor strength, 340, 343 testosterone and, 514 strength of, by age, 347, 352 Bone density, measurements of, in male Back supports (Posture Training Support), osteoporosis, 314 in osteoporosis, 353-354, 355, 358, Bone loss, in women, 263-264 359, 360 pathophysiology of, 259-270 Bacterial vaginosis, 641 —642 Bone markers, effects of salmon nasal spray Balance, changes in, computerized dynamic calcitonin on, 389 posturography to assess, 349 Bone mass, calcium and, 326 Behavioral emergencies, management of, 712 effects of withdrawal of parathyroid hormone on, 428—429 Benzodiazepines, 710 exercises to improve, 341 electroconvulsive therapy and, 832 measurements of, 281—297 devices for, WHO criteria for, Binge drinking, 748—750 282-283, 284 Biphosphonates, in osteoporosis, 499 monitoring of, 289-294 vitamin D and, 327 Bipolar disorder, 786—794 antidepressants in, 794 Bone mineral density, 245, 246 antipsychotics in, 793 cigarette smoking and, 248, 251 carbamazepine in, 793 effect of hormone replacement therapy demographic factors in, 788—789 on, 364—365, 368 differential diagnosis of, 789-790 effects of calcitonin on, 384 lithium in, 791-792 effects of salmon nasal spray calcitonin nonpharmacologic treatment in, 794 on, 385—387 presentation of, 787—788 fracture risk and, 250 prognosis in, 789 protein intake and, 327-328 treatment of, 790-794 Bone remodeling, 259-262 valproate in, 792—793 aging and, 263-267 Bipolar disorders, antidepressants in, 699 as systematic process, 262 function of, 260—261 Bisphosphonate(s), 397-416 phases of, 259, 260 binding to bone, 397 combined with other agents, 408 Boron, effect on bone, 331 compared, for tolerability, 407-408 Brace, to prevent lumbar and thoracic flexion, efficacy of, compared, 407 356, 359 for treatment of osteoporosis, 397-416 general side effects and toxicity of, 408 Brain, space-occupying lesions of, electrocon- in development, 406 vulsive therapy in, 831 mechanism of action of, 398-399 Brain aging, accelerated, and Alzheimer’s structure(s) of, 397, 398 disease, 623-624 uses of, 397 Brain tumors, electroconvulsive therapy a-Blockers, sexual function and, 558 in, 831 8-Blockers, sexual function and, 558, 559 Breast cancer, altered expression of, in Body mass index, and back strength, by age, estrogen deficiency, 621-623 347, 352 raloxifene in, 376—377 by age, 347 sexual function and, 468 tamoxifen in, 373, 374—375, 377 Bone, cancellous, changes in remodeling of, with age, 263-266 Breathing, sleep-disordered, 183-185 cortical, changes in remodeling of, with in elderly patients, 184—185 age, 266—267 Breathlessness. See Dyspnea. density of, impact of estrogen on, 365 long, fractures of, in osteoporosis, ortho- Bronchial obstruction, at end of life, manage- pedic management of, 437-459 ment of, 229 860 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 Bronchodilators, in asthma, 68—70 Candidiasis, vulvovaginal, 642-643 in dyspnea, 231-232 Capgras syndrome, 805 Bronchoscopy, in lung cancer, Carbamazepine, 709 Bupropion, in depression, 702 in bipolar disorder, 793 Buspirone, 710—711 Carcinomatous lymphangitis, at end of life, management of, 231 Cc Cardiac disease, suspected, dyspnea in, 28 Cardiovascular disease, accelerated, in Caffeine. intake of, and calcium balance, 329 estrogen deficiency, 618-619 CAGE questionnaire, 750 electroconvulsive therapy in, 831 in postmenopausal period, 495—496 Calcitonin, 383-396 sexual dysfunction and, 569 analgesic effects of, 390-391 testosterone and, 514—515 effects on bone mineral density, 384 effects on fracture, 384 Cardiovascular health, of older in combination therapy, 392 homosexuals, 589 glucocorticoid-induced osteoporosis, 390 Care planning. See Advanced care planning. osteoporosis in older woman, treat- Caregiving, changing roles and, 601 ment of, 383—384 injectable, in postmenopausal osteoporo- Central nervous system, disorders of, restric- sis, 384 tive pulmonary syndrome in, 193 nasal, in older women, administration efferent impulse of, dyspnea and, 23 and side effects of, 391 integration/processing in, dyspnea resistance to, 391 and, 22 role of, in treatment of postmenopausal Cerebrovascular accidents, sexual dysfunction osteoporosis, 392 —393 and, 568 salmon nasal spray, effect on fracture reduction, 389 Cerebrovascular disease, as cause of manic effects on bone markers, 389 symptoms, 790 effects on fracture, 387-388 electroconvulsive therapy in, 831 in men with idiopathic osteoporo- impact on mood disorders, 778-779 sis, 389-390 Cervicitis, 639-640, 641 in postmenopausal osteoporosis, gonococcal and chlamydial, 639, 641 384-389 Chancroid, 644—645 Calcium, and bone mass, 326 as essential nutrient, 323 Chemotherapeutic agents, sexual function balance of, and cafeine intake, 329 and, 560 osteoporosis and, 497-498 daily dietary intake of, estimation of, 324 Chest radiograph, to diagnose pulmonary daily intake of, 325-326 embolism, 159-160 excretion of, salt and, 328 Chlamydial cervicitis, 639, 641 in calcium supplements, 324 mean fractional absorption of, 323 Cholinesterase inhibitors, 711 recommended intake of, 323-324 in dementia, 817 vitamin D, and fractures, 327 Chronic obstructive pulmonary disease, 40—42 and nutrition, in elderly adults, advanced care planning in, 226 323-337 mechanical ventilation in, 216 Cancer, and older homosexuals, 588 —5 89 respiratory failure in, 207—208 colorectal, accelerated, in estrogen defi- Citalopram, 698 ciency, 621 erectile dysfunction in, 532 Clodronate, clinical trials of, 404 of breast, altered expression of, in estro- current use of, 405 gen deficiency, 621 —623 Clomipramine, effect on sexual function, 554 sexual function and, 468 sexual dysfunction and, 566—567 Clonazepam, 710 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 Clozapine, 705, 712—713 clinical features and pathology of, in dementia, 816 765-766 clinical history of, 764 Cognition, in perimenopausal syndrome, 488—489 electroconvulsive therapy in, 818 end-of-life care in, 848-851 Cognitive impairment, 672-677 etiology of, 810-812 incidence of, 673 issues in diagnosis and treatment of, sexuality and, 602 763-764 neurotransmitter correlates in, 768—769 Cognitive problems, in men, 609-610 Parkinson, 771—772 Colorectal cancer, accelerated, in estrogen prevalence of, 672, 673, 674, 676 deficiency, 621 risk factors for, 673 stages of, 848-849 Computed tomography, in lung cancer, vascular, 770—771 141-142 weight loss and aspiration pneumonia spiral, to diagnose pulmonary embolism, in, 849 163-164 WHO definition of, 764 with behavioral and psychologic Connective tissue, disorders of, and symptoms, 799-825 osteoporosis, 306, 309 agitation in, 802, 803 “Cortical steal” phenomenon, 429 anxiety in, 806 apathy in, 806-807 Corticosteroids, in dyspnea, 232 caregivers in, 818 clinical symptoms of, 802-804 Cough, at end of life, management of, 235 delusions and hallucinations in, pathophysiology of, 234 803-804 Cough reflex, during normal aging of depression in, 807—808 respiratory system, 9 development of term, 800-801 economics of, 818—819 Coughing, assisted, in restrictive pulmonary environment and, 809-810 syndrome, 199-200, 201 pharmacologic interventions in, 812-818 Counseling, for patients with medical psychosis in, 812 conditions, 600—601 psychotherapies in, 810 in erectile dysfunction, 535 sleep disturbances in, 802—803 prevention, 597, 598 wandering, 808-809 with Lewy bodies, 771 D Depression, and anxiety disorders, 672 as psychologic outcome of osteoporosis, D-dimer concentration, in pulmonary 273-274 embolism, 160-161 dysthymic, 779 Delirium, costs of, 847 end-of-life care in, 842—844 diagnosis of, 846 erectile dysfunction in, 532 end-of-life care in, 845—848 executive dysfunction in, 784 medications associated with development in ischemic heart disease, antidepressants of, 847 in, 699 prevalence and incidence of, 846 late life, assessment and diagnosis of, treatment of, 847-848 777-786 biological risk factors for, Dementia(s), 672—677 781-783 adverse outcomes of, 677 mortality associated with, 781 AIDS-related, and Alzheimer’s disease, psychosocial risk factors for, 783 features of, 651 risk factors for, 781 —783 AiZiieimer’s disease and, 763—776 subsymdromal, 779 antibiotics in, 849 treatment of, 783—785 antidepressants in, 814 palliative care in, 843—844 anxiety in, 680 poststroke, antidepressants in, 699 behavioral symptoms in, 849-850 psychotic symptoms and, 684 cholinergic deficits in, 767-768 treatment of, in primary care, 785 862 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 Dextroamphetamine, in depression, 702 mechanisms of, 20-21 mechanoreceptors and, 21 —22 Diabetes, electroconvulsive therapy in, 831-832 pathophysiology of, 227-228 erectile dysfunction in, 531 pharmacologic treatment of, at end of life, 231-234 new-onset, antipsychotics and, 705 sexual dysfunction and, 568—569 prevalence of, in elderly, 19-20 sexual function and, 468 psychotropic medications in, 31 ratings of, during exercise and aging, 24 Digoxin, sexual function and, 559 sensation of, receptor sites in, 2] —22 treatment of, 29-31 Disease, sexuality and, 563-573 upper extremity resistance training in, 30 Diuretics, electroconvulsive therapy and, 833 ventilatory muuscle training in, 30—31 sexual function and, 557 Donepezil, in dementia, 817 Drinking, binge, 748—750 E and concomitant drug use, 750 Echocardiography, to diagnose pulmonary continuous, versus intermittent, 743 embolism, 162 Drug(s), adverse reactions to, antipsychotics Ejaculation, disorders of, 531 and, 704—705 as cause of erectile dysfunction, 477 Elderly. See Older adults. oral, in erectile dysfunction, 533-534 Electrocardiogram, in pulmonary Drug-drug interactions, 712, 713 embolism, 160 Drug therapy, in osteoporosis, 498-499 Electroconvulsive therapy, adverse effects of, 828, 835-836 DSM criteria, to assess mood disorders, anesthetic agents for, 834—835 777-779 caffeine in, 835 cardiovascular agents for, 834 Duloxetine, 702 cardiovascular complications of, 835 Dysphoria, testosterone and, in men, 608 —609 continuation, 837 contraindications to, 830 Dyspnea, alternative medicine modalities electrode placement for, 833-834 in, 233 evaluation prior to, 830 assessment of, history and symptom frequency and number of treatments with, scales in, 228 836-837 physical examination and diagnos- future directions in, 838 tic testing in, 228-229 headache in, 836 at end of life, 225 in dementia, 818 breathing training in, 29 elderly, 827-840 causes of, management considerations major depression, 828— 829 and, 229-231 mania, 829 characteristics of, 25, 26 medical conditions, 830 chemoreceptors and, 21 schizophrenia, 829 chronic, evaluation of, physical findings indications for, 826 for, 25—26 maintenance, 837 unexplained, 28—29 mechanism of action of, 827-828 coping stategies in, 29— 30 muscle relaxants in, 835 definition of, 19, 225 postictal delirium in, 836 during normal aging of respiratory premedications for, 834 system, 8—9 prolonged apnea in, 835 efferent impulse of CNS and, 23 prolonged seizures with, 835 elderly patient with, approach to, 24—28 risks of use of, 831—832 evaluation of, in older adults, 19-33 exercise training/reconditioning in, 30 Electrolyte disturbances, electroconvulsive in suspected cardiac disease, 28 therapy in, 832 in suspected respiratory disease, 28 Embolism, pulmonary. See integration/processing in CNS and, 22 Pulmonary embolism. intensity of, lung involvement and anxi- ety and, 225-226 Emphysema, senile, 4 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 863 End-of-life, management of respiratory Exercise(s), and compression fractures, 352, symptoms at, 225-238 354, 358 and osteoporosis, 352—354 End-of-life care, caregiver issues at, 851—852 dyspnea rating during, 24 in anxiety, 844—845 nonstrenuous, in severe osteoporosis, in delirium, 845—848 350-351 dementia, 848-851 program of, in osteoporosis, physical depression, 842—844 examination prior to, 356—360 geriatric psychiatry, 841-856 to improve bone mass, 341 psychologic considerations in, 841—842 to strengthen back, 341 Endocrine disorders, osteoporosis and, Exercise capacity, during normal aging of 304-306 respiratory system, 12-13 Endotracheal intubation, ventilator-associated Exhibitionism, as paraphilia, 631 —632 pneumonia and, 217—218 Epilepsy, electroconvulsive therapy in, 838 Erectile dysfunction, 529-538 F and disease, 565—566 causes of, in older men, 476—477 Falls, as risk factor for fracture, 251 definition of, 539 Family history, as risk for fractures, 251 epidemiologic aspects and prevalence of, of patients with osteoporosis, 302 529-530 risk for osteoporosis and, 248 etiology and treatment of, 539-551 etiology of, 541, 543, 544 Femoral neck fractures, 442—444 evaluation and treatment of, incidence of, 539 Femur, distal, supracondylar fractures of, medical conditions associated with, 531, 446-448 Fetishes, and paraphilia, 633-634 study of, methods in, 540 results of, 540—543 Fist fornication, 635 treatment of, 533 543 Fluoride, dietary sources of, 331 Frection, neural pathways controlling, 474 excess ingestion of, 331 Eroticism, anal, 634—635 Follicle stimulating hormone, menopause and, 464 Estrogen, deficiency of, following menopause, Food and Drug Administration, monitoring of 464-465 bone mass measurements and, 289 impact on bone density, 365 parathyroid hormone and, in Food groups, effect on bone health, 332 osteoporosis, 425—426, 427 progestogens with, effect on bone Fracture(s). See also specific sites and types of density, 365 fractures. use in older women, 617-627 as consequence of bone loss, 341 compression, exercise and, 352, Estrogen deficiency, pathophysiology of, on in osteoporosis, 343 bone metabolism, 364 effects of calcitonin on, 384 effects of salmon nasal spray calcitonin Estrogen deficiency state, clinical consequen- on, 387—388 ces of, 617—624 epidemiology of, 249-250 Estrogen preparations, vaginal, 465-466 falls as risk factor for, 251 family history as risk for, 251 Estrogen/progestin hormone therapy, study fragility, consequences of, 249—250 of, 495 risk for future fractures and, 301 healing of, and stability of, augmentation Estrogen-receptor modulators, selective, of, 439-442, 443 373-381 intertrochanteric, and sliding hip screw, Etidronate, clinical trials of, 403—404 444-446, 447 current use of, 404 location of, diagnostic implications of, tolerability and side effects of, 404 301-302 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 management of, clinical strategies in, Genital ulcer disease, 643 442-453 Geriatric Depression Scale (GDS), 665 in osteoporosis, 438—439, 440, 441 postoperative care in, Geriatric Mental State Schedule 453-456 (AGECAT), 665 of ankle, antiglideplate and, 449, 450 of hip. See Hip, fractures of. Glucocorticoid-induced osteoporosis, calcito- of proximal humerus, tension band fix- nin in, 390 ation in, 450—451, 452 parathyroid hormone in, 426 of spine, osteoporosis-related, sedatives Gonococcal cervicitis, 639, 641 and physical therapy in, 346 of wrist, management of, 451 —452 Gonococcal infections, treatment for, 638, 639 osteoporosis-related, 437 personal history of, and risk for, 250-251 prevention of, 339 H probability of, 249 Health care, avoidance of, by rates of, across ethnicities, NORA data homosexuals, 591] on, 282, 283 Health care providers, discussion of sexuality reduction of, effects of salmon nasal by, 596 spray calcitonin on, 389 health care of homosexuals and, risk factors for, 250—252 risk of, NORA dataset for, 282 590—591 prediction of, NORA studies of, Heart failure, congestive, advanced care plan- 286-289 ning in, 226 supracondylar, of distal femur, 446—448 at end of life, management of, 230 tibial plateau, lateral, and rafter plate, 448 —449 Herpes, genital, 643-644 vertebral, and long bone, in osteoporosis, treatment of, 644 orthopedic management of, Hiccups, at end of life, management of, 437-459 235-236 in osteoporosis, 452 —453, pathophysiology of, 234 454-455 prevention of, hormone replace- Hip, fracture(s) of, 363 ment therapy in, 366-368 complications of, 344, 345 vitamin D, and calcium, 327 diagnosis of, 344 wedging and compression, osteoporosis- missed, 344 related, 342, 343 osteoporotic, 496 prevention of, hormone replacement Fregoli syndrome, 806 therapy in, 366-367 Frontotemporal dementia, 772 risk factors for, 301 risk of, fractures contributing to, 344-345 G HIV and AIDS, in older adult, 647-652 Galantamine, in dementia, 817 diagnosis of, 648—651 management of, 651 —652 Gas exchange, during normal aging of respira- risk factors for, 647—648 tory system, 9—11 in older homosexuals, 589 Gastrointestinal disorders, in osteoporosis, Home-based mechanical ventilation, 220 307-308 Homophobia, as health care barrier to homo- Gastrointestinal medications, sexual function sexuals, 590 and, 559-560 Homosexual(s), older, 587-593 Gender, as factor in risk for osteoporosis, 247 behavioral health and, 588 cancer and, 588—589 Generalized anxiety disorder, prevalence of, cardiovascular health and, 589 677, 680 community support for, 592 Genital herpes, 643-644 financial rights of, 591 treatment of, 644 health care of, barriers to, 590—591 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 health studies and, 587—589 HIV and AIDS in, 589 Incontinence, sexual dysfunction and, 566 living situation of, 591 mental health and, 588 infantilism, paraphilic, 634 social support for, 592 Infiltrative disorders, in osteoporosis, 307 unique concerns of, 602 Insomnia, 181—183 Hormonal changes, with menopause, 464—465 Intermittent positive pressure ventilation, lip seal for, 195, 196 Hormone replacement therapy, 469 noninvasive, 198—199, 200 adverse effects of, 368-369 benefit of, for elderly postmenopausal Internal fixation, in fractures in osteoporosis, woman, 624 437, 438 duration of, and impact of withdrawal Intertrochanteric fractures, and sliding hip of, 368 screw, 444—446, 447 effect on bone mineral density, 364-365, 368 Intracavernosal injection therapy, in erectile effect on incidence of breast cancer, 6 dysfunction, 479-480 21-622 Ischemic heart disease, depression in, antide- efficacy of, 364-368 pressants in, 699 for prevention of fractures of hip, 366-367 for prevention of vertebral fractures, K 366-368 Kidney disease, psychopharmacology in, in perimenopausal syndrome, 491—492 713-714 in postmenopausal osteoporosis, 363-372 Knee, extensor strength, 340 risk of Alzheimer’s disease and, 623, 624 Kyphosis, in osteoporosis, 343-344 Women’s Health Initiative study of, = 369-370 Hot flashes, in perimenopausal syndrome, L 486-487 Laboratory evaluation, in osteoporosis, treatment of, in perimenopausal 309-311 syndrome, 492—493 Lamotrigine, 710 Humerus, proximal, fractures of, tension band L-dopa/carbidopa, electroconvulsive therapy fixation in, 450—451, 452 and, 833 Hyperlipidemia, antipsychotics and, 705 Libido, testosterone and, 467, 511 with age, 467 Hyperparathyroidism, primary, parathyroid hormone therapy and, 418—420 Life, quality of, and general versus disease- targeted quality of life scales, 277 Hypertension, erectile dysfunction in, and osteoporosis-targeted quality of 531-532, 545 life scales, 276-277 osteoporosis and, 275—276 Hyperthyroidism, electroconvulsive therapy future directions in, 277—278 in, 832 psychosocial outcomes and interventions for, Hypnotics, 711 271-280 Hypoglycemic agents, electroconvulsive Limbs, periodic movements of, during therapy and, 833 sleep, 186 Hypogonadism, erectile dysfunction in, Lipid-lowering agents, sexual function 532-533, 541, 543-545 and, 559 Hypothalamic-pituitary-gonadal axis, systemic Lithium, 707—708 diseases and, 564 electroconvulsive therapy and, 833 in bipolar disorder, 791 —792 Hypothalamic-pituitary-testicular axis, with precautions in use of, 791—792 aging, 510 side effects of, 708 866 Cumulative Index / Clin Geriatr Med 19 (2003) 857-873 Liver disease, psychopharmacology in, 713 home-based, 220 in chronic obstructive pulmonary disease, Longitudinal Aging Study (Amsterdam), 208, 216 779-780 in respiratory failure, 205 Lung(s), cancer of, cell types of, 140 diagnosis of, and screening for, Medical illness, anxiety and, 726-727 sexual function and, 467-469 140-145 in elderly, 139-155 Medication asistance programs, pharmaceutical staging of, 145-149 company-sponsored, 714 treatment of, in elderly, 149-152 Medications. See also Drug(s). chronic obstructive disease of, 40—42 and sexual function, 553-562, 601 embolism of. See Pulmonary embolism. associated with osteoporosis, 306, 309 function of, aging and, 23—24 for asthma therapy, 66—70 in relation to aging, 191 function testing and, 48—49 Men, disorders of sexual function in, 473—482 impairment of, definition of, 189-191 Menopause, 483-504 multifaactorial risk indices and, 46—48 average age of, 484 postoperative complications of, age as clinical approach to, 485 risk factor for, 36—39 estrogen deficiency following, 464—465 cigarette use and, 39-40 follicle stimulating hormone and, 464 genral health status and, 44 hormonal changes with, 464—465 in asthma, 42 induced, 483 obesity and, 42—44 natural, 483 patient-related risk factors for, pathophysiology of, 484-485 39-44 symptoms of, impacting sexual function, risk factors for, 49, 50 465 —467 preoperative assessment of, in older transition to, 483 adult, 35-55 procedure-related risk factors and, Mental disorders, implicetions of, for geriatric anesthesia as, 45—46 medicine, 688 neuromuscular blocking agent late-life, epidemiology of, 663-696 and, 46 prevalence of, 664—668 surgery and, 45 Methylphenidate, in depression, 702 Lung scanning, ventilation-perfusion, to diag- nose pulmonary embolism, 162-163 Mini-Mental State Examination (MMSE), 665 Lung volumes, during normal aging of respi- Mirtazapine, in depression, 702 ratory system, 6—7 Mood and sleep disorders, treatment of, in Lymphangitis, carcinomatous, at end of life, perimenopausal syndrome, 494 management of, 231 Mood disorders, categories of, 779 in older populations, prevalence of, 666-667, 668-672 M in perimenopausal syndrome, 489-490 Magnesium, recommended intake of, 330 late life, 777-797 Magnetic resonance imaging, to diagnose Mood stabilizers, 707 —708 pulmonary embolism, 161-162 Movement disorders, induced by antipsy- Major depressive disorder, 779 chotics, 703-704 Malignancies, in osteoporosis, 307 Muscle(s), bulbar, weakness of, causes of, 190 Mania, electroconvulsive therapy in, 829 Muscle fibers, reduction of, in aging, 352 Manic episode(s), criteria for, 787 differential diagnosis of, 789-790 Muscle loss, osteoporosis and, 339-341 MAOIs, in depression, 702 Muscular dysfunction, elderly patients with, Masturbation, and paraphilia, 632 pulmonary physical medicine interven- tions for, 189-204 Mechanical ventilation, acute respiratory dis- tress syndrome and, 209, 211 Musculoskeletal disorders, sexual function costs of, in elderly patients, 216—217 and, 468